Outcomes of patients with DLBCL-RS undergoing auto-HCT or allo-HCT
| Outcomes . | Allo-HCT (n =118) . | Auto-HCT (n =53) . | ||
|---|---|---|---|---|
| n . | Prob, % (95% CI) . | n . | Prob, % (95% CI) . | |
| Neutrophil recovery | 117 | 52 | ||
| 1 mo | 96 (91-99) | 98 (89-100) | ||
| Platelet recovery | 114 | 51 | ||
| 100 d | 93 (87-97) | 96 (86-100) | ||
| Grade 2-4 acute GVHD | 91 | N/A | N/A | |
| 100 d | 34 (25-44) | |||
| 6 mo | 39 (29-49) | |||
| Grade 3-4 acute GVHD | 91 | N/A | N/A | |
| 100 d | 12 (6-20) | |||
| 6 mo | 13 (7-21) | |||
| Chronic GVHD | 100 | N/A | N/A | |
| 1 y | 37 (27-46) | |||
| 2 y | 41 (31-51) | |||
| NRM | 114 | 49 | ||
| 100 d | 11 (6-17) | 4 (0-11) | ||
| 1 y | 23 (16-31) | 10 (3-21) | ||
| 3 y | 27 (19-36) | 15 (6-26) | ||
| Relapse/progression* | 114 | 49 | ||
| 1 y | 23 (16-31) | 29 (17-42) | ||
| 3 y | 30 (22-39) | 37 (24-51) | ||
| PFS | 114 | 49 | ||
| 1 y | 54 (45-63) | 61 (47-74) | ||
| 3 y | 43 (34-52) | 48 (34-62) | ||
| OS | 118 | 53 | ||
| 1 y | 69 (60-77) | 73 (61-84) | ||
| 3 y | 52 (43-61) | 57 (43-70) | ||
| Outcomes . | Allo-HCT (n =118) . | Auto-HCT (n =53) . | ||
|---|---|---|---|---|
| n . | Prob, % (95% CI) . | n . | Prob, % (95% CI) . | |
| Neutrophil recovery | 117 | 52 | ||
| 1 mo | 96 (91-99) | 98 (89-100) | ||
| Platelet recovery | 114 | 51 | ||
| 100 d | 93 (87-97) | 96 (86-100) | ||
| Grade 2-4 acute GVHD | 91 | N/A | N/A | |
| 100 d | 34 (25-44) | |||
| 6 mo | 39 (29-49) | |||
| Grade 3-4 acute GVHD | 91 | N/A | N/A | |
| 100 d | 12 (6-20) | |||
| 6 mo | 13 (7-21) | |||
| Chronic GVHD | 100 | N/A | N/A | |
| 1 y | 37 (27-46) | |||
| 2 y | 41 (31-51) | |||
| NRM | 114 | 49 | ||
| 100 d | 11 (6-17) | 4 (0-11) | ||
| 1 y | 23 (16-31) | 10 (3-21) | ||
| 3 y | 27 (19-36) | 15 (6-26) | ||
| Relapse/progression* | 114 | 49 | ||
| 1 y | 23 (16-31) | 29 (17-42) | ||
| 3 y | 30 (22-39) | 37 (24-51) | ||
| PFS | 114 | 49 | ||
| 1 y | 54 (45-63) | 61 (47-74) | ||
| 3 y | 43 (34-52) | 48 (34-62) | ||
| OS | 118 | 53 | ||
| 1 y | 69 (60-77) | 73 (61-84) | ||
| 3 y | 52 (43-61) | 57 (43-70) | ||
N/A, not applicable; Prob, probability.
Histology at relapse (CLL/SLL vs DLBCL-RS) was not available; therefore, any relapse was considered an event.